Document:

Exhibit 10.5

 

[FORM
OF] SERIES A WARRANT

 

THE
WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS IN RELIANCE ON EXEMPTIONS FROM REGISTRATION REQUIREMENTS
UNDER SAID LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED
UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS,
OR (2) THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY
TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS.

 

THE
TRANSFER OF THIS WARRANT IS RESTRICTED AS DESCRIBED HEREIN.

 

CALETHOS
INC.

 

Series
A Warrant for the Purchase of up to _____ Shares of

Common
Stock, par value $0.001 per share

 

	No.
    WA-__	_____  Shares
	Issue
    Date: ______________	

 

THIS
CERTIFIES that, for value received, ______________________, with an address at _____________________________________________________
(including any transferee, the “Holder”), is entitled to subscribe for and purchase from CalEthos Inc., a Nevada
corporation (the “Company”), upon the terms and conditions set forth herein, at any time or from time to time
before 5:00 P.M., New York time, on February 28, 2023 (the “Exercise Period”), up to _________________ (_____)
shares of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company at an initial exercise
price per share of $1.50, subject to adjustment pursuant to the terms hereof (the “Exercise Price”). As used
herein, the term “this Series A Warrant” shall mean and include this Series A Warrant and any Series A Warrant or
Series A Warrants hereafter issued as a consequence of the exercise or transfer of this Series A Warrant in whole or in part.

 

The
number of shares of Common Stock issuable upon exercise of this Series A Warrant (the “Series A Warrant Shares”)
and the Exercise Price may be adjusted from time to time as hereinafter set forth.

 

1.
(a) This Series A Warrant may be exercised during the Exercise Period as to all or a lesser number of whole Series A Warrant Shares
by the surrender of this Series A Warrant (with the Exercise Form attached hereto duly executed) to the Company at its principal
executive office, which is located on the date hereof at 11753 Willard Avenue, Tustin, CA 92782, Attention: Chief Financial Officer,
or at such other place as is designated in writing by the Company, together with cash, a certified or bank cashier’s check
or wire transfer of immediately available funds payable to the order of the Company in an amount equal to the Exercise Price multiplied
by the number of Series A Warrant Shares for which this Series A Warrant is being exercised. Upon the exercise of this Series
A Warrant pursuant to this Section 1(a), the Holder shall receive, in addition to the Series A Warrant Shares for which this Series
A Warrant is exercised, a new stock purchase warrant (a “Series B Warrant”) to purchase a number of shares
of Common Stock equal to the number of Series A Warrant Shares purchased at an exercise price equal to $1.50 per share, subject
to adjustment. The Series B Warrant shall be exercisable to purchase shares of Common Stock at any time, or from time-to-time,
up to and including 5:00 P.M., New York time, on the third anniversary date of the date of the issuance of the Series B Warrant;
provided, however, if such date is not a Business Day, then on the Business Day immediately following such date.

 

    	 

    	 

    

 

(b)
This Series A Warrant may also be exercised by the Holder through a cashless exercise, as described in this Section 1(b). This
Series A Warrant may be exercised, in whole or in part, by (i) the delivery to the Company of a duly executed Exercise Form specifying
the number of Series A Warrant Shares to be applied to such exercise, and (ii) the surrender to a common carrier for overnight
delivery to the Company, or as soon as practicable following the date the Holder delivers the Exercise Form to the Company, of
this Series A Warrant (or an indemnification undertaking with respect to this Series A Warrant in the case of its loss, theft
or destruction). The number of shares of Common Stock to be issued upon exercise of this Series A Warrant pursuant to this Section
1(b) shall equal the value of this Series A Warrant (or the portion thereof being canceled) computed as of the date of delivery
of this Series A Warrant to the Company using the following formula:

 

	X
    = 	Y(A-B)

    A

where:

 

	 	X  =
    the number of shares of Common Stock to be issued to the Holder under this Section 1(b);
	 	Y  =
    the number of Series A Warrant Shares identified in the Exercise Form as being applied to the subject exercise;
	 	A  =
    the Current Market Price on such date; and
	 	B  =
    the Exercise Price on such date

 

For
purposes of this Section 1(b), the “Current Market Price” per share of Common Stock on any day shall mean:
(i) if the principal trading market for such securities is a national or regional securities exchange, the closing price on such
exchange on such day; or (ii) if (i) above is not applicable, and if bid and ask prices for shares of Common Stock are reported
in the over-the-counter market of the OTC Markets Group, Inc., the average of the high bid and low ask prices so reported on such
day. Notwithstanding the foregoing, if there is no reported closing price or bid and ask prices, as the case may be, for the day
in question, then the Current Market Price shall be determined as of the latest date prior to such day for which such closing
price or bid and ask prices, as the case may be, are available, unless such securities have not been traded on an exchange or
in the over-the-counter market for 30 or more days immediately prior to the day in question, in which case the Current Market
Price shall be determined in good faith by, and reflected in a formal resolution of, the Board of Directors of the Company.

 

The
Company acknowledges and agrees that this Series A Warrant was issued on the Issue Date set forth on the face of this Series A
Warrant (the “Issuance Date”). Consequently, the Company acknowledges and agrees that, if the Holder conducts
a cashless exercise pursuant to this Section 1(b), the period during which the Holder held this Series A Warrant may, for purposes
of Rule 144 promulgated under the Securities Act of 1933, as amended (the “Act”), be “tacked” to
the period during which the Holder holds the Series A Warrant Shares received upon such cashless exercise.

 

2.
Upon each exercise of the Holder’s rights to purchase Series A Warrant Shares, the Holder shall be deemed to be the holder
of record of the Series A Warrant Shares issuable upon such exercise, notwithstanding that the transfer books of the Company shall
then be closed or certificates representing such Series A Warrant Shares shall not then have been actually delivered to the Holder.
As soon as practicable after each such exercise of this Series A Warrant, the Company shall issue and deliver to the Holder a
certificate or certificates for the Series A Warrant Shares issuable upon such exercise, registered in the name of the Holder
or its designee. If this Series A Warrant should be exercised in part only, the Company shall, upon surrender of this Series A
Warrant for cancellation, execute and deliver a new Series A Warrant evidencing the right of the Holder to purchase the balance
of the Series A Warrant Shares (or portions thereof) subject to purchase hereunder.

 

    	2

    	 

    

 

3.
(a) Any Series A Warrants issued upon the registration of transfer or exercise in part of this Series A Warrant shall be numbered
and shall be registered in a Series A Warrant Register as they are issued. The Company shall be entitled to treat the registered
holder of any Series A Warrant on the Series A Warrant Register as the owner in fact thereof for all purposes and shall not be
bound to recognize any equitable or other claim to or interest in such Series A Warrant on the part of any other person, and shall
not be liable for any registration or transfer of Series A Warrants which are registered or to be registered in the name of a
fiduciary or the nominee of a fiduciary unless made with the actual knowledge that a fiduciary or nominee is committing a breach
of trust in requesting such registration or transfer, or with the knowledge of such facts that its participation therein amounts
to bad faith. The transfer of this Series A Warrant may be registered on the books of the Company upon delivery thereof duly endorsed
by the Holder or by his duly authorized attorney or representative, or accompanied by proper evidence of succession, assignment
or authority to transfer. In all cases of transfer by an attorney, executor, administrator, guardian or other legal representative,
due authority shall be produced. Upon any registration of transfer, the Company shall deliver a new Series A Warrant or Series
A Warrants to the person entitled thereto. This Series A Warrant may be exchanged, at the option of the Holder thereof, for another
Series A Warrant, or other Series A Warrants of different denominations, of like tenor and representing in the aggregate the right
to purchase a like number of Series A Warrant Shares (or portions thereof), upon surrender to the Company or its duly authorized
agent. Notwithstanding the foregoing, the Company may require prior to registering any transfer of a Series A Warrant an opinion
of counsel reasonably satisfactory to the Company that such transfer complies with the provisions of the Act, and the rules and
regulations thereunder.

 

(b)
The Holder acknowledges that he has been advised by the Company that neither this Series A Warrant nor the Series A Warrant Shares
have been registered under the Act, that this Series A Warrant is being or has been issued and the Series A Warrant Shares may
be issued on the basis of the statutory exemption provided by Section 4(2) of the Act or Rule 506 of Regulation D promulgated
thereunder, or both, relating to transactions by an issuer not involving any public offering, and that the Company’s reliance
thereon is based in part upon the representations made by the original Holder in the Subscription Agreements. The Holder acknowledges
that he has been informed by the Company of, or is otherwise familiar with, the nature of the limitations imposed by the Act and
the rules and regulations thereunder on the transfer of securities. In particular, the Holder agrees that no sale, assignment
or transfer of this Series A Warrant or the Series A Warrant Shares issuable upon exercise hereof shall be valid or effective,
and the Company shall not be required to give any effect to any such sale, assignment or transfer, unless (i) the sale, assignment
or transfer of this Series A Warrant or such Series A Warrant Shares is registered under the Act, it being understood that neither
this Series A Warrant nor such Series A Warrant Shares are currently registered for sale and that the Company has no obligation
or intention to so register this Series A Warrant or such Series A Warrant Shares except as specifically provided for in the Registration
Rights Agreement (as defined or described in the Subscription Agreement), or (ii) this Series A Warrant or such Series A Warrant
Shares are sold, assigned or transferred in accordance with all the requirements and limitations of Rule 144 under the Act, it
being understood that Rule 144 is not available at the time of the original issuance of this Series A Warrant for the sale of
this Series A Warrant or such Series A Warrant Shares and that there can be no assurance that Rule 144 sales will be available
at any subsequent time, or (iii) such sale, assignment, or transfer is otherwise exempt from registration under the Act in the
opinion of counsel reasonably acceptable to the Company.

 

    	3

    	 

    

 

4.
The Company shall at all times reserve and keep available out its authorized and unissued Common Stock, solely for the purpose
of providing for the exercise of the rights to purchase all Series A Warrant Shares granted pursuant to the Series A Warrants,
such number of shares of Common Stock as shall, from time to time, be sufficient therefor. The Company covenants that all shares
of Common Stock issuable upon exercise of this Series A Warrant, upon receipt by the Company of the full Exercise Price therefor,
shall be validly issued, fully paid, nonassessable, and free of preemptive rights.

 

5.
(a) In case the Company shall at any time after the date the Series A Warrants were first issued (i) declare a dividend on the
outstanding Common Stock payable in shares of its capital stock, (ii) subdivide the outstanding Common Stock, (iii) combine the
outstanding Common Stock into a smaller number of shares, or (iv) issue any shares of its capital stock by reclassification of
the Common Stock (including any such reclassification in connection with a consolidation or merger in which the Company is the
continuing corporation), then, in each case, the Exercise Price, and the number of Series A Warrant Shares issuable upon exercise
of this Series A Warrant, in effect at the time of the record date for such dividend or of the effective date of such subdivision,
combination or reclassification, shall be proportionately adjusted so that the Holder after such time shall be entitled to receive
the aggregate number and kind of shares which, if such Series A Warrant had been exercised immediately prior to such time, he
would have owned upon such exercise and been entitled to receive by virtue of such dividend, subdivision, combination or reclassification.
Such adjustment shall be made successively whenever any event listed above shall occur.

 

(b)
In case the Company shall issue or fix a record date for the issuance to all holders of Common Stock of rights, options, or warrants
to subscribe for or purchase Common Stock (or securities convertible into or exchangeable for Common Stock) at a price per share
(or having a conversion or exchange price per share, if a security convertible into or exchangeable for Common Stock) less than
the then applicable Exercise Price per share on such record date, then, in each case, the Exercise Price shall be adjusted by
multiplying the Exercise Price in effect immediately prior to such record date by a fraction, the numerator of which shall be
the number of shares of Common Stock outstanding on such record date plus the number of shares of Common Stock which the aggregate
offering price of the total number of shares of Common Stock so to be offered (or the aggregate initial conversion or exchange
price of the convertible or exchangeable securities so to be offered) would purchase at such Exercise Price and the denominator
of which shall be the number of shares of Common Stock outstanding on such record date plus the number of additional shares of
Common Stock to be offered for subscription or purchase (or into which the convertible or exchangeable securities so to be offered
are initially convertible or exchangeable). Such adjustment shall become effective at the close of business on such record date;
provided, however, that, to the extent the shares of Common Stock (or securities convertible into or exchangeable for shares of
Common Stock) are not delivered, the Exercise Price shall be readjusted after the expiration of such rights, options, or warrants
(but only with respect to warrants exercised after such expiration), to the Exercise Price which would then be in effect had the
adjustments made upon the issuance of such rights, options, or warrants been made upon the basis of delivery of only the number
of shares of Common Stock (or securities convertible into or exchangeable for shares of Common Stock) actually issued. In case
any subscription price may be paid in a consideration part or all of which shall be in a form other than cash, the value of such
consideration shall be as determined in good faith by the board of directors of the Company, whose determination shall be conclusive.

 

    	4

    	 

    

 

(c)
In case the Company shall distribute to all holders of Common Stock (including any such distribution made to the stockholders
of the Company in connection with a consolidation or merger in which the Company is the continuing corporation) evidences of its
indebtedness, cash (other than any cash dividend which, together with any cash dividends paid within the 12 months prior to the
record date for such distribution, does not exceed 5% of the then applicable Exercise Price at the record date for such distribution)
or assets (other than distributions and dividends payable in shares of Common Stock), or rights, options or warrants to subscribe
for or purchase Common Stock, or securities convertible into or exchangeable for shares of Common Stock (excluding those with
respect to the issuance of which an adjustment of the Exercise Price is provided pursuant to Section 5(b) hereof), then, in each
case, the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date for
the determination of stockholders entitled to receive such distribution by a fraction, the numerator of which shall be the then
applicable Exercise Price per share of Common Stock on such record date, less the fair market value (as determined in good faith
by, and reflected in a formal resolution of, the board of directors of the Company, whose determination shall be conclusive absent
manifest error) of the portion of the evidences of indebtedness or assets so to be distributed, or of such rights, options or
warrants or convertible or exchangeable securities, or the amount of such cash, applicable to one share, and the denominator of
which shall be such Exercise Price per share of Common Stock. Such adjustment shall become effective at the close of business
on such record date.

 

(d)
No adjustment in the Exercise Price shall be required if such adjustment is less than $.01; provided, however, that any adjustments
which by reason of this Section 5(d) are not required to be made shall be carried forward and taken into account in any subsequent
adjustment. All calculations under this Section 5 shall be made to the nearest cent or to the nearest one-thousandth of a share,
as the case may be.

 

(e)
In any case in which this Section 5 shall require that an adjustment in the Exercise Price be made effective as of a record date
for a specified event, the Company may elect to defer, until the occurrence of such event, issuing to the Holder, if the Holder
exercised this Series A Warrant after such record date, the shares of Common Stock, if any, issuable upon such exercise over and
above the shares of Common Stock, if any, issuable upon such exercise on the basis of the Exercise Price in effect prior to such
adjustment; provided, however, that the Company shall deliver to the Holder a due bill or other appropriate instrument evidencing
the Holder’s right to receive such additional shares upon the occurrence of the event requiring such adjustment.

 

(f)
Upon each adjustment of the Exercise Price as a result of the calculations made in Sections 5(b) or 5(c) hereof, this Series A
Warrant shall thereafter evidence the right to purchase, at the adjusted Exercise Price, that number of shares (calculated to
the nearest thousandth) obtained by multiplying (A) the number of shares purchasable upon exercise of this Series A Warrant prior
to such adjustment by (B) a fraction, the numerator of which is the Exercise Price in effect prior to such adjustment and the
denominator of which is the Exercise Price in effect immediately after such adjustment.

 

(g)
Whenever there shall be an adjustment as provided in this Section 5, the Company shall promptly cause written notice thereof to
be sent by registered mail, postage prepaid, to the Holder, at its address as it shall appear in the Series A Warrant Register,
which notice shall be accompanied by an officer’s certificate setting forth the number of Series A Warrant Shares purchasable
upon the exercise of this Series A Warrant and the Exercise Price after such adjustment and setting forth a brief statement of
the facts requiring such adjustment and the computation thereof, which officer’s certificate shall be conclusive evidence
of the correctness of any such adjustment absent manifest error.

 

(h)
The Company shall not be required to issue fractions of shares of Common Stock or other capital stock of the Company upon the
exercise of this Series A Warrant. If any fraction of a share would be issuable on the exercise of this Series A Warrant (or specified
portions thereof), the Company shall purchase such fraction for an amount in cash equal to the same fraction of the Exercise Price
of such share of Common Stock on the date of exercise of this Series A Warrant.

 

    	5

    	 

    

 

6.
(a) In case of any consolidation or combination with or merger of the Company with or into another corporation or entity (other
than a merger, consolidation or combination in which the Company is the surviving or continuing corporation), or in case of any
sale, lease or conveyance to another corporation, entity or person of the property and assets of any nature of the Company as
an entirety or substantially as an entirety, or any compulsory share exchange, pursuant to which share exchange the Common Stock
is converted into other securities, cash or other property (collectively an “Extraordinary Event”), then, as
a condition of such reorganization, reclassification, consolidation, merger, sale, transfer or other disposition, lawful and adequate
provision shall be made whereby the Holder shall thereafter have the right to purchase and receive upon the basis and upon the
terms and conditions herein specified and in lieu of the Series A Warrant Shares immediately theretofore issuable upon exercise
of this Series A Warrant, such shares of stock, securities or assets as would have been issuable or payable with respect to or
in exchange for a number of Series A Warrant Shares equal to the number of Series A Warrant Shares immediately theretofore issuable
upon exercise of this Series A Warrant, had such Extraordinary Event not taken place, and in any such case appropriate provision
shall be made with respect to the rights and interests of the Holder to the end that the provisions hereof (including, without
limitation, provision for adjustment of the Exercise Price) shall thereafter be applicable, as nearly equivalent as may be practicable
in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof. The Company shall not
effect any such Extraordinary Event unless prior to or simultaneously with the consummation thereof the successor corporation
(if other than the Company) resulting from such Extraordinary Event shall assume the obligation to deliver to the Holder, at the
last address of the Holder appearing on the books of the Company, such shares of stock, securities or assets as, in accordance
with the foregoing provisions, the Holder may be entitled to purchase, and the other obligations under this Series A Warrant.
The provisions of this paragraph shall similarly apply to successive Extraordinary Events.

 

(b)
In case of any reclassification or change of the shares of Common Stock issuable upon exercise of this Series A Warrant (other
than a change in par value or from no par value to a specified par value, or as a result of a subdivision or combination, but
including any change in the shares into two or more classes or series of shares), or in case of any consolidation, combination
or merger of another corporation or entity into the Company in which the Company is the continuing corporation and in which there
is a reclassification or change (including a change to the right to receive cash or other property) of the shares of Common Stock
(other than a change in par value, or from no par value to a specified par value, or as a result of a subdivision or combination,
but including any change in the shares into two or more classes or series of shares), the Holder shall have the right thereafter
to receive upon exercise of this Series A Warrant solely the kind and amount of shares of stock and other securities, property
or cash, or any combination thereof receivable upon such reclassification, change, consolidation, combination or merger by a holder
of the number of shares of Common Stock for which this Series A Warrant might have been exercised immediately prior to such reclassification,
change, consolidation, combination or merger. Thereafter, appropriate provision shall be made for adjustments, which shall be
as nearly equivalent as practicable to the adjustments in Section 5.

 

(c)
The above provisions of this Section 6 shall similarly apply to successive reclassifications and changes of shares of Common Stock
and to successive consolidations, combinations, mergers, sales, leases or conveyances.

 

    	6

    	 

    

 

7.
In case at any time the Company shall propose to:

 

(a)
pay any dividend or make any distribution on shares of Common Stock in shares of Common Stock or make any other distribution (other
than regularly scheduled cash dividends which are not in a greater amount per share than the most recent such cash dividend) to
all holders of Common Stock; or

 

(b)
issue any rights, warrants or other securities to all holders of Common Stock entitling them to purchase any additional shares
of Common Stock or any other rights, warrants or other securities; or

 

(c)
effect any reclassification or change of outstanding shares of Common Stock, or any consolidation, merger, sale, lease or conveyance
of property or other Extraordinary Event; or

 

(d)
effect any liquidation, dissolution or winding-up of the Company; or

 

(e)
take any other action which would cause an adjustment to the Exercise Price;

 

then,
and in any one or more of such cases, the Company shall give written notice thereof, by registered mail, postage prepaid, to the
Holder at the Holder’s address as it shall appear in the Series A Warrant Register, mailed at least 15 days prior to (i)
the date as of which the holders of record of shares of Common Stock to be entitled to receive any such dividend, distribution,
rights, warrants or other securities are to be determined, (ii) the date on which any such reclassification, change of outstanding
shares of Common Stock, consolidation, merger, sale, lease, conveyance of property, liquidation, dissolution or winding-up is
expected to become effective, and the date as of which it is expected that holders of record of shares of Common Stock shall be
entitled to exchange their shares for securities or other property, if any, deliverable upon such reclassification, change of
outstanding shares, consolidation, merger, sale, lease, conveyance of property, liquidation, dissolution, or winding-up, or (iii)
the date of such action which would require an adjustment to the Exercise Price.

 

8.
The issuance of any shares or other securities upon the exercise of this Series A Warrant, and the delivery of certificates or
other instruments representing such shares or other securities, shall be made without charge to the Holder for any tax or other
charge in respect of such issuance. The Company shall not, however, be required to pay any tax which may be payable in respect
of any transfer involved in the issue and delivery of any certificate in a name other than that of the Holder and the Company
shall not be required to issue or deliver any such certificate unless and until the person or persons requesting the issue thereof
shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax
has been paid.

 

9.
The Series A Warrant Shares issued upon exercise of this Series A Warrant shall be subject to a stop transfer order and the certificate
or certificates evidencing such Series A Warrant Shares shall bear the following legend:

 

“THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR
OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS, OR (2) THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION
ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE
MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS.”

 

10.
Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction or mutilation of any Series A Warrant (and
upon surrender of any Series A Warrant if mutilated), the Company shall execute and deliver to the Holder thereof a new Series
A Warrant of like date, tenor and denomination.

 

    	7

    	 

    

 

11.
The holder of this Series A Warrant shall not have solely on account of such status, any rights of a stockholder of the Company,
either at law or in equity, or to any notice of meetings of stockholders or of any other proceedings of the Company, except as
provided in this Series A Warrant.

 

12.
Any term of this Series A Warrant may be amended or waived upon the written consent of the Company and the holders of Series A
Warrants representing at least 50% of the number of shares of Common Stock then subject to all outstanding Series A Warrants (the
“Majority Holders”); provided, that (x) any such amendment or waiver must apply to all Series A Warrants; and
(y) the number of Series A Warrant Shares subject to this Series A Warrant, the Exercise Price and the Exercise Period may not
be amended, and the right to exercise this Series A Warrant may not be altered or waived, without the written consent of the Holder.

 

13.
This Series A Warrant has been negotiated and consummated in the State of New York and shall be governed by, and construed in
accordance with the laws of the State of New York applicable to contracts made and performed within such State, without regard
to principles governing conflicts of law. The Company and, by accepting this Series A Warrant, the Holder, each irrevocably submits
to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District
Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising
out of this Series A Warrant and the transactions contemplated hereby. Service of process in connection with any such suit, action
or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of
notices under the Subscription Agreements. The Company and, by accepting this Series A Warrant, the Holder, each irrevocably consents
to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. The Company
and, by accepting this Series A Warrant, the Holder, each irrevocably waives any objection to the laying of venue of any such
suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought
in any such court has been brought in an inconvenient forum. EACH OF THE COMPANY AND, BY ITS ACCEPTANCE HEREOF, THE HOLDER
HEREBY WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS WARRANT AND REPRESENTS THAT COUNSEL
HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

Dated:
__________, 2020

 

	 	CalEthos
    Inc.
	 	 	         
	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	8

    	 

    

 

CALETHOS
INC.

 

FORM
OF ASSIGNMENT

 

(To
be executed by the registered holder if such holder

desires
to transfer the attached Series A Warrant.)

 

	To:	CalEthos
    Inc.
	 	11753
    Willard Avenue
	 	Tustin,
    CA 92782
	 	Attention:  Michael
    Campbell

 

FOR
VALUE RECEIVED, _______________ hereby sells, assigns, and transfers unto _______________ that certain Series A Warrant (Number
WA-______) to purchase __________ shares of Common Stock, par value $0.001 per share, of CalEthos Inc. (the “Company”),
together with all right, title, and interest therein, and does hereby irrevocably constitute and appoint ________________________
attorney to transfer such Series A Warrant on the books of the Company, with full power of substitution.

 

Dated:
_________

 

Signature: _________________________________

 

Notice:                                                                       

 

The
signature on the foregoing Assignment must correspond to the name as written upon the face of this Series A Warrant in every particular,
without alteration or enlargement or any change whatsoever.

 

    	 

    	 

    

 

CALETHOS
INC.

 

EXERCISE
FORM

 

(To
be completed and signed only upon exercise of the Series A Warrants)

 

	To:	CalEthos
    Inc.
	 	11753
    Willard Avenue
	 	Tustin,
    CA 92782
	 	Attention:  Michael
    Campbell

 

The
undersigned hereby exercises his or its rights to purchase ___________ Series A Warrant Shares covered by the within Series A
Warrant and tenders payment herewith in the amount of $_________ by [tendering cash, a wire of immediately available funds or
delivering a certified check or bank cashier’s check, payable to the order of the Company] [surrendering ______ shares of
Common Stock received upon exercise of the attached Series A Warrant, which shares have a Current Market Price equal to such payment]
in accordance with the terms thereof, and requests that certificates for such securities be issued in the name of, and delivered
to:

 

	 	 
	 	 
	 	 
	 	 
	 	 
	 	(Print
    Name, Address and Social Security
	 	or
    Tax Identification Number)

 

and,
if such number of Series A Warrant Shares shall not be all the Series A Warrant Shares covered by the within Series A Warrant,
that a new Series A Warrant for the balance of the Series A Warrant Shares covered by the within Series A Warrant be registered
in the name of, and delivered to, the undersigned at the address stated below.

 

	Dated:
    ____________, ________	Name:	 
	 	 	(Please
    Print)
	 	 	 
	        	Address:	 
		 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	(Signature)Exhibit 4.12

 

 

WARRANT AMENDMENT AGREEMENT

 

THIS WARRANT AMENDMENT
AGREEMENT (this “Agreement”) is made as of March 3, 2020, by and among Titan Pharmaceuticals, Inc.,
a Delaware corporation (the “Company”) and _______________ and ______________ (collectively
with their permitted assigns, the “Holders”).

 

RECITALS

 

WHEREAS, the Holders
are the registered and beneficial owners of (i) a warrant issued to ________ dated January 9, 2020 to purchase ________ shares
of the Company’s common stock at an exercise price of $0.25 per share[, and (ii) a warrant issued to ________August 9, 2019
to purchase ____________ shares of the Company’s common stock at an exercise price of $1.07 per share] (collectively, the
 “Existing Warrants”); and

 

WHEREAS, the Company
and the Holders desire to amend the Existing Warrants to modify the circumstances under which the Holders may receive a cash payment
in the event of the occurrence of a Fundamental Transaction (capitalized terms used herein without definition shall have the meaning
ascribed to such terms in the Existing Warrants); and

 

WHEREAS, pursuant to
Section 5(l) of each of the Existing Warrants, the Existing Warrants may be amended with the written consent of the Company and
the respective Holder.

 

NOW, THEREFORE, in
consideration of the foregoing recitals and the mutual promises, representations, warranties and covenants hereinafter set forth
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:

 

1. Amendment to
Existing Warrants. Section 3(d) of each of the Existing Warrants is hereby deleted and replaced in its entirety with the following:

 

(d) Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person or

 

     

     

    

 

group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise
of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation
in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise
of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction other than one in which a Successor
Entity (as defined below) that is a publicly traded corporation whose stock is quoted or listed on a Trading Market assumes this
Warrant such that the Warrant shall be exercisable for the publicly traded common stock of such Successor Entity, the Company or
any Successor Entity shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the
consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction),
purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining
unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, if the
Fundamental Transaction is not within the Company’s control, including not approved by the Company’s Board of Directors
or the consideration is not in all stock of the Successor Entity, Holder shall have the option to require the Company or any Successor
Entity to purchase its Warrant for the Black Scholes Value of the unexercised portion of this Warrant as of the date of consummation
of such Fundamental Transaction using the same type or form of consideration (and in the same proportion) that is being offered
and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration
be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive
from among alternative forms of consideration in connection with the Fundamental Transaction. Any cash payment will be made by
wire transfer of immediately available funds within five Business Days of the Holder’s election (or, if later, on the effective
date of the Fundamental Transaction). “Black Scholes Value” means the value of this Warrant based on the Black and
Scholes Option Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest
rate

 

    2

     

    

 

corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100
day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement
of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the
price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental
Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Termination Date. The payment of the Black Scholes Value will be made by wire transfer of immediately available
funds within five Business Days of the Holder’s election (or, if later, on the effective date of the Fundamental Transaction).
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor
Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions
of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by
the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to
the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant
(without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of
the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that
from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company”
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.

 

2. Effectiveness
 This Agreement and the amendment to each of the Existing Warrants described in Section 1 hereof shall be effective as of the
date first above written.

 

3. Waivers and Amendments.
The terms of this Agreement may be waived or amended with the written consent of the Company and the Holders.

 

4. Governing Law. This Agreement
shall be governed in all respects by and construed in accordance with the laws the State of New York, without any regard to conflicts
of laws principles.

 

    3

     

    

 

5. Successors and Assigns. The provisions
hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the
parties to this Agreement.

 

6. Counterparts. This Agreement may
be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be executed and delivered by their respective duly authorized officers as of the date
first above written.

 

TITAN PHARMACEUTICALS,
INC.

 

 

By:___________________________

      Name:

      Title:

[____________________________]

 

By: _________________________________

Name:

Title:

 

[____________________________]

 

By: _________________________________

Name:

Title:

 

    4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]